Cetuximab continues to increase survival in patients with head and neck cancer for up to 5 years

November 06, 2009

Adding cetuximab to radiation therapy prolongs survival in patients with locally advanced head and neck cancer compared with radiotherapy alone, and this improvement persists for up to 5 years. As such, this combined treatment should be considered as a standard option for patients with advanced head and neck cancer, concludes an Article published Online First in The Lancet Oncology.

Standard treatment for head and neck cancer is radiotherapy in combination with surgery. The use of chemoradiotherapy has been shown to improve survival and has become a popular treatment, but is not ideal because of its associated side-effects and increased toxicity.

Most head and neck cancers express the epidermal growth factor receptor (EGFR), which is linked to poor clinical outcome and decreased response to radiotherapy. However, cetuximab is a monoclonal antibody that targets EGFR, and has been shown to enhance the effect of radiotherapy and inhibit tumour growth in preclinical studies.

In 1999, a trial commenced to examine the effect of adding cetuximab to radiotherapy in patients with locally advanced head and neck cancers of the oropharynx, hypopharynx, and larynx. In total, 424 patients were randomly assigned to 6𔃅 weeks of radiotherapy alone (213) or radiotherapy and cetuximab (211). The primary results of the trial showed that patients treated with cetuximab had a 13% improvement in absolute disease control and 10% improvement in absolute survival at 3 years without increased side-effects, compared with patients given radiotherapy alone.

In this study, James Bonner and colleagues report the long-term 5-year outcomes of patients involved in the original trial.

Overall, findings showed an improvement in absolute survival of about 9% in patients given cetuximab compared with those given radiotherapy alone (36.4% vs 45.6%) at 5 years.

Interestingly, the authors found that patients treated with cetuximab who developed a prominent cetuximab-induced acne-like rash showed significantly improved overall survival compared with patients given cetuximab who developed a mild or no rash (more than 68.8 months vs 25.6 months). They suggest that the rash could be a biomarker for an immunological response that is associated with a favourable outcome.

Further analyses also showed that various patient and tumour factors (such as having an oropharynx tumour, being male, and aged less than 65 years) were associated with an improved benefit from combined treatment with cetuximab and radiotherapy compared with radiotherapy alone.

The authors conclude: "Future studies will be designed to help provide a pathway to individualised patient treatments. The analysis of molecular markers...will help refine our ability to select the patients who will benefit from the various systemic treatments to radiotherapy."
-end-
Professor James A Bonner, The University of Alabama at Birmingham, AL, USA. T) +1 205 934-7185 E) gesims@uabmc.edu

For full Article see: http://press.thelancet.com/tlobonner.pdf

Lancet

Related Radiotherapy Articles from Brightsurf:

Genomic analysis predicts survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in low-grade gliomas in NRG Oncology clinical trial
A practice-changing study, NRG Oncology clinical trial NRG-RTOG 9802, has demonstrated, for the first time, a survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in certain subgroups of patients with high-risk, low-grade glioma (WHO classification: LGG, grade II), a type of brain tumor that originates from glial cells.

Outcomes in radiotherapy-treated patients with cancer during COVID-19
The delivery of radiotherapy in 209 patients with cancer during the COVID-19 outbreak in Wuhan, China, is evaluated in this case series.

Shorter radiotherapy treatment for bowel cancer patients during COVID-19
An international panel of cancer experts has recommended a one-week course of radiotherapy and delaying surgery as the best way to treat patients with bowel cancer during the COVID-19 pandemic.

The pros and cons of radiotherapy: Will it work for you?
Women undergoing radiotherapy for many cancers are more likely than men to be cured, but the side effects are more brutal, according to one of Australia's most experienced radiation oncology medical physicists.

How to keep boron inside cells during radiotherapy: a novel approach to cancer treatment
Boron neutron capture therapy (BNCT) is a technique in which p-boronophenylalanine (BPA) is transferred to cancer cells, and the boron in it undergoes nuclear fission reaction upon irradiation of thermal neutrons, releasing high energy particles that kill the cells.

Prolonged breath-holding could help radiotherapy treatment of cardiac arrhythmias
A technique that enables patients suffering from heart conditions to hold their breath safely for over five minutes could have potential as part of a new treatment for cardiac arrhythmias, say researchers at the University of Birmingham.

Zebrafish 'avatars' can help decide who should receive radiotherapy treatment
To date, there is no method for clearly determining whether radiotherapy will be an effective treatment for individual cancer patients.

One dose of radiotherapy as effective as five doses for cancer in the spine
A single dose of radiotherapy is as 'effective' as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.

Personalized and powerful: UK to lead next-generation radiotherapy research
The UK will be transformed into a global hub for radiotherapy research, pioneering the use of the latest techniques such as FLASH radiotherapy and artificial intelligence, with a new £56 million research network announced by Cancer Research UK today.

Oxygen in hyperbaric chamber provides relief after radiotherapy
Hyperbaric oxygen therapy (HBOT) can relieve self-reported symptoms and side-effects of radiotherapy against cancer in the pelvic region, a study shows.

Read More: Radiotherapy News and Radiotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.